no desc

New 2021 publication about the benefits of Trimetazidine and Bisoprolol to treat symptomatic patients with Chronic Coronary Syndrome

The 2019 ESC guidelines for the diagnostic and management of Chronic Coronary Syndrome (CCS) acknowledge that cardiac ischemia has different facets and that the treatment of patients with chronic coronary syndrome should be adapted to each patients' characteristics and preferences1.

Ischemic heart disease being the first cause of death worldwide2, an adequate management of patients is essential to curb the progression to more severe heart diseases, such as heart failure. Servier offers several solutions for these symptomatic patients with chronic coronary syndrome.


Despite the widespread use of Beta Blocker, a high proportion of patients with stable angina continue to experience ischemia and anginal pain. The early combination Vastarel + Beta-Blocker reduces the angina attacks and improves exercise capacity of angina patients

Download the full content

New Publication 2021

  1. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes​


It can also interest yo

Disease Awareness

February 11, 2022


March 20, 2022
Managing the treatment of angina according to identified underlying mechanisms 1


March 11, 2022
Triple Therapies Webinar – Single Pill Combination a perfect macht between clin…
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.